Merck KGaA (MKKGY)
- Previous Close
28.49 - Open
27.84 - Bid 27.74 x 312600
- Ask 27.84 x 41800
- Day's Range
27.71 - 27.84 - 52 Week Range
24.32 - 39.17 - Volume
2,348 - Avg. Volume
125,126 - Market Cap (intraday)
57.642B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
19.00 - EPS (TTM)
1.46 - Earnings Date May 15, 2025
- Forward Dividend & Yield 0.50 (1.76%)
- Ex-Dividend Date Apr 29, 2025
- 1y Target Est
37.10
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
www.merckgroup.com/en59,020
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MKKGY
View More
Related Videos: MKKGY
Performance Overview: MKKGY
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MKKGY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MKKGY
View MoreValuation Measures
Market Cap
60.51B
Enterprise Value
69.09B
Trailing P/E
19.54
Forward P/E
13.26
PEG Ratio (5yr expected)
1.43
Price/Sales (ttm)
2.57
Price/Book (mrq)
1.81
Enterprise Value/Revenue
2.88
Enterprise Value/EBITDA
10.22
Financial Highlights
Profitability and Income Statement
Profit Margin
13.13%
Return on Assets (ttm)
5.10%
Return on Equity (ttm)
9.82%
Revenue (ttm)
21.16B
Net Income Avi to Common (ttm)
2.78B
Diluted EPS (ttm)
1.46
Balance Sheet and Cash Flow
Total Cash (mrq)
3.08B
Total Debt/Equity (mrq)
34.35%
Levered Free Cash Flow (ttm)
1.66B
Research Analysis: MKKGY
View MoreResearch Reports: MKKGY
View MoreMerck KGaA Earnings: All Three Businesses Return to Growth, Leaving Destocking Behind
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
RatingPrice TargetMerck KGaA Earnings: Life Science Rebound Underway and 2024 Guidance Intact
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
RatingPrice TargetMerck KGaA Earnings: Raises 2024 Outlook Slightly, but No Fair Value Estimate Change
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
RatingPrice TargetMerck KGaA Earnings: Raises 2024 Outlook Slightly, but No Fair Value Estimate Change
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
RatingPrice Target